



TIRmed Pharma initiates collaboration with ERBC for regulatory safety studies ahead of its first clinical trial

TIRmed Pharma, a biotechnology company developing next-generation treatments for autoimmune skin diseases, has entered into a collaboration with ERBC, a leading European CRO specialized in toxicology studies. The partnership covers two regulatory safety studies, marking the final steps ahead of the company's planned Phase I clinical trial in 2026.



These studies represent the final preclinical steps for TIR-C, TIRmed's topical drug candidate for the treatment of atopic dermatitis (eczema). The first safety study has already begun, and the second is expected to start shortly. The studies address both systemic and dermal safety in accordance with regulatory requirements.

"These are the final safety studies before entering the clinic – a critical milestone in our development program," says Leo Holmgren, CEO of TIRmed Pharma. "ERBC's experience with this type of study makes them a valuable partner, and with their support, we are confident in generating the data needed to move into Phase I next year."

TIRmed Pharma is advancing a next-generation treatment for atopic dermatitis, designed to offer patients an effective treatment with fewer side effects and simpler administration. The treatment targets the root causes of the disease rather than merely alleviating symptoms. In preclinical studies, five topical applications over two weeks have resulted in up to 15 months of sustained relief.

For more information, please contact:

Leo Holmgren, CEO

Phone: +46 70 049 18 42

Email: leo.holmgren@tirmedpharma.com

About TIRmed Pharma

TIRmed Pharma is a biotechnology company developing next-generation immunomodulatory therapies for autoimmune skin diseases, with an initial focus on atopic dermatitis (eczema). The company's drug candidate, TIR-C, is a topical oligonucleotide-based treatment that regulates immune responses and targets the disease's underlying mechanisms. Promising preclinical results support its potential to provide long-lasting relief and reduce treatment burden. Building on expertise in immunology and drug development, the company is pioneering new solutions in dermatological immunotherapy to enable more targeted and effective treatment options. TIRmed Pharma is headquartered in Stockholm, Sweden. For more information, visit tirmedpharma.com and follow TIRmed on [LinkedIn](#).

About ERBC

ERBC is a leading European contract research organization (CRO) specializing in non-clinical studies. With over 50 years of experience, ERBC offers comprehensive preclinical services, including discovery, regulatory toxicology, safety pharmacology, and laboratory sciences, to support the pharmaceutical, biotechnology, chemical, and medical device industries. The company operates six sites across Europe, providing GLP and non-GLP studies with in vitro and in vivo models, including non-human primates, to assess the safety and efficacy of new compounds. ERBC is committed to advancing science responsibly by integrating the principles of Replacement, Reduction, and Refinement (3Rs) in animal research and delivering high-quality data to facilitate the transition from preclinical to clinical development. For more information, visit <http://www.erbc-group.com/>.